Copyright
©The Author(s) 2019.
World J Hepatol. Jun 27, 2019; 11(6): 522-530
Published online Jun 27, 2019. doi: 10.4254/wjh.v11.i6.522
Published online Jun 27, 2019. doi: 10.4254/wjh.v11.i6.522
Variables | Β ± SE | P value |
Model 1, demographic variables | ||
Age | -0.001 ± 0.001 | 0.871 |
Sex | 0.062 ± 0.167 | 0.710 |
PPI use | 0.607 ± 0.180 | 0.001b |
Model 2, medical comorbidities | ||
Age | 0.002 ± 0.008 | 0.787 |
Sex | 0.043 ± 0.166 | 0.797 |
MELD Score | 0.020 ± 0.011 | 0.079 |
PPI Use | 0.607 ± 0.179 | < 0.001b |
Model 3, other medications | ||
Age | 0.004 ± 0.008 | 0.647 |
Sex | 0.033 ± 0.164 | 0.839 |
MELD Score | 0.024 ± 0.011 | 0.041a |
Lactulose | 0.324 ± 0.189 | 0.089 |
PPI use | 0.625 ± 0.178 | < 0.001b |
- Citation: Fasullo M, Rau P, Liu DQ, Holzwanger E, Mathew JP, Guilarte-Walker Y, Szabo G. Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients. World J Hepatol 2019; 11(6): 522-530
- URL: https://www.wjgnet.com/1948-5182/full/v11/i6/522.htm
- DOI: https://dx.doi.org/10.4254/wjh.v11.i6.522